Actively Recruiting
Phase IaIb Study of GH2616 Tablet to Evaluate Safety, Tolerability, and Early Effectiveness in Adults with Advanced Solid Tumors
Led by Suzhou Genhouse Bio Co., Ltd. · Updated on 2024-07-08
156
Participants Needed
1
Research Sites
18 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a Phase IaIb clinical trial to study GH2616 Tablet in adults with advanced solid tumors. The study aims to evaluate the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early anti-tumor activity of GH2616. The trial includes patients with tumors such as ovarian, uterine, lung, breast, bladder, and colorectal cancers, especially those with TP53 mutation and whole genome duplication WGD. The study is sponsored by Suzhou Genhouse Bio Co., Ltd.
CONDITIONS
Brief Title
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Research Team
S
SHIYA CHEN, bachelor
Z
ZHENGBO SONG, Doctorate
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
